Perspective Therapeutics begins recruitment of second dosing cohorts

Perspective Therapeutics announced that it began patient recruitment for the second dosing cohorts in clinical studies for both of its lead product candidates, 212PbVMT-alpha-NET and 212PbVMT01, after the safety monitoring committees for each study unanimously recommended moving forward. In addition, the first patient in cohort 2 of the 212PbVMT01 study was already dosed. “We continue to make rapid progress across all of our clinical programs and demonstrate the promise of our targeted alpha radioligand therapies to provide needed treatment options for patients with intractable tumors,” commented Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics. “Preliminary safety data from these Phase 1 studies of 212PbVMT-alpha-NET and 212PbVMT01 demonstrate good tolerability and support further dose escalation. The 212PbVMT-alpha-NET data are consistent with the data collected at similar doses from the clinician-initiated ongoing study in India. We look forward to providing further safety and efficacy updates in the second half of 2024.”